Hematologic Disorders

Jan 20, 2022| Posted in: Cancers, Hematologic Disorders, News, Treatment

Talquetamab + Daratumumab Is Well Tolerated in Relapsed/Refractory Multiple Myeloma Patients

Dr. Ajai Chari at the Mount Sinai School…
Jan 19, 2022| Posted in: Cancers, Diagnosis, Drug Development, Hematologic Disorders, Treatment

Treatment Benefit of Daratumumab for Multiple Myeloma Supported by 3-Year Follow-Up Data

Dr. Jacob Laubach of the Dana-Farber Cancer Institute…
Jan 13, 2022| Posted in: Cancers, Diagnosis, Drug Development, Hematologic Disorders, Treatment

What Physicians Can Learn About CML Treatment from the OPTIC Trial 

Dr. Thihan Padukkavidana of Takeda Oncology discusses what…
Jan 11, 2022| Posted in: Drug Development, Hematologic Disorders, News, Treatment

Positive Results from PRINCE Study of Pegcetacoplan in PNH Patients

Dr Monica Fay of Apellis Pharmaceuticals discusses results…
Jan 10, 2022| Posted in: Congenital And Genetic Conditions, Drug Development, Hematologic Disorders, News

Gene Editing Therapy Shows Promise for Sickle Cell Anemia 

Philippe Duchateau, PhD of Cellectis discusses the company’s…
Jan 6, 2022| Posted in: Cancers, Diagnosis, Drug Development, Hematologic Disorders

Disease-Free Survival vs. Progression-Free Survival in Cancer Studies

Dr Paolo Ghia discusses the difference between disease-free…
Jan 5, 2022| Posted in: Cancers, Diagnosis, Drug Development, Hematologic Disorders

Safety of the Bispecific Antibody, REGN5458, in Multiple Myeloma Patients

Dr. Jeffrey Zonder, MD, of the Barbara Ann…
Jan 4, 2022| Posted in: Autoimmune / Autoinflammatory Disorders, Cancers, Congenital And Genetic Conditions, Drug Development, Endocrine Disorders, Gastrointestinal Diseases, Hematologic Disorders, Kidney And Urinary Diseases, Lung Diseases, Lysosomal Storage Disorders, Metabolic Disorders, Musculoskeletal Diseases, Neurology/Nervous System Diseases, News, Ophthalmology/Eye Diseases, Regulations, Skin Conditions, Treatment

2022 Orphan Drugs: PDUFA Dates and FDA Approvals

Almost half of all novel medications approved by…
Dec 23, 2021| Posted in: Cancers, Drug Development, Hematologic Disorders, News

Sustained uMRD Demonstrated in Elderly CLL Patients Receiving Ibrutinib Plus Venetoclax

Dr. Arnon Kater from the University of Amsterdam discusses new…
Dec 20, 2021| Posted in: Cancers, Hematologic Disorders, News

Subasumstat + Rituximab Is Tolerable in Subsets of Non-Hodgkin Lymphoma Patients

Karuppiah Kannan, Senior Director at Takeda, discusses early…

CME Program: Gaucher Disease Highlights from WORLDSymposium 2020

Neal Weinreb, MD, FACP highlights the latest information about Gaucher disease from WORLDSymposium and provides expert analysis of its clinical relevance to help health care providers better care for patients with this rare disease.

TTR Amyloidosis CME Program

Morie A Gertz, MD, MACP provides an overview of TTR Amyloidosis – including how to shorten individuals’ diagnostic journey and the time till they access treatment which might improve their quality of life or even prevent disease progression – through these brief courses that are certified for CME credit.

Rare Disease Clinical Trials CME Program

Learn about clinical trials and rare diseases through these brief courses that are certified for CME and CNE credit.
  • Heather Lau, MD, MS, NYU School of Medicine, New York, NY
  • Morie A Gertz, MD, Mayo Clinic, Rochester, MN
  • Timothy Craig, DO, Penn State University, Hershey, PA
  • Eric T. Wong, MD, Harvard Medical School, Boston, MA

Hematologic Disorders

Topics